Professor Tan Shao Weng, Daniel, aged 47, has been an Independent Non-executive Director and a member of the Technical Committee of HUTCHMED since October 2025. With over 20 years of experience in clinical oncology, his research focuses on thoracic and head and neck malignancies, drug development, and biomarker-driven therapies.

Professor Tan is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the National Cancer Centre Singapore (NCCS). He also serves as a professor at Duke-NUS Medical School and a senior clinician-scientist at the Genome Institute of Singapore. He leads the Experimental Cancer Therapeutics Unit (ECRU) at the NCCS, one of Asia’s largest Phase I units. He is also the Principal Investigator of the Cancer Therapeutics Research Laboratory at NCCS focused on developing representative patient-derived preclinical models to study drug response and resistance. He currently serves as the principal investigator of the National Medical Research Council (“NMRC”) Lung Cancer Large Collaborative Grant in Singapore (2025-2029 and previously 2019–2023) and chairs the Asian Thoracic Oncology Research Group, a regional platform for translational research and clinical trials. He is also currently a director of Epoch Biosciences Pte. Ltd. He has contributed to over 200 peer-reviewed articles in journals such as Nature, Nature Medicine, and The Lancet Oncology.

Professor Tan holds a Bachelor of Science with first-class honors in tumor biology from University College London, a Bachelor of Medicine and Surgery from St Bartholomew’s and the Royal London School of Medicine and Dentistry, and a PhD from the National University of Singapore. He is a member of the Royal College of Physicians of the United Kingdom and serves in leadership roles in global oncology, including Chair of the IASLC Education Committee.